ClinicalTrials.gg
Not yet recruitingNCT07857265Updated Oct 15, 2026

Mass Balance Study of [14C]DA-302168S in Healthy Chinese Adult Male Participants

A Phase 1 interventional study of [14C] DA-302168S in Healthy Adult Subjects, sponsored by Chendu DIAO Pharmaceutical Group CO., LTD.. Not yet recruiting. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Chendu DIAO Pharmaceutical Group CO., LTD. · Phase 1, Interventional, and Treatment

Updated Oct 15, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

In this study, a single dose of [14C] radiolabelled DA-302168S will be administered orally. The main purpose of this study is to find out how much of DA-302168S and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral [14C] DA-302168S.

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Chendu DIAO Pharmaceutical Group CO., LTD. is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants aged 18-55 years inclusive at ICF signing.
  • At screening, weight ≥50.0 kg and 19.0-28.0 kg/m² inclusive.
  • Male participants must agree to use reliable for themselves and their partners during the study and for 1 year after dosing (see Appendix 2), and not donate sperm for assisted reproduction.
  • Able to understand the study procedures and methods, voluntarily sign the ICF, and willing to strictly comply with the protocol and complete the study.
  • Detailed medical history, physical examination, vital signs, laboratory tests [CBC, blood chemistry, coagulation, urinalysis, stool routine and occult blood, thyroid function (FT3, FT4, TSH), , amylase, lipase, serum calcitonin], 12-lead , chest X-ray (PA), digital rectal examination, and abdominal ultrasound (liver, gallbladder, pancreas, spleen, both kidneys) show no abnormalities or no abnormalities.

Exclusion criteria

Exclusion Criteria:

  • History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or MEN2; or serum calcitonin ≥50 ng/L at screening.
  • History of chronic pancreatitis, or acute pancreatitis within 3 months before ICF signing.
  • History of acute gallbladder disease within 3 months before ICF signing.
  • Any within 5 years before ICF signing (except basal cell carcinoma treated with curative therapy and considered cured).
  • History of serious cardiovascular, neuropsychiatric, gastrointestinal, respiratory, urinary, or endocrine disease within 1 year before ICF signing (e.g., acute myocardial infarction, major depression, gastric ulcer, uremia).
  • As judged by the investigator, dysphagia at screening, or concurrent conditions that may affect drug absorption, distribution, metabolism, or excretion, such as active inflammatory bowel disease, gastrectomy, or any intestinal resection.
  • Severe hypoglycemia within 3 months before screening.
  • History of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), or known intolerance or allergy to GLP-1R agonists.
  • Hemorrhoids, or perianal disease with regular/current hematochezia, irritable bowel syndrome, or inflammatory bowel disease.
  • Habitual constipation or diarrhea.
  • Blood donation or major bleeding (≥400 mL) within 3 months before screening, or between screening and first dose.
  • History of drug abuse within 3 years before screening (e.g., morphine, ketamine, THC acid, methamphetamine, MDA, cocaine), or positive urine drug test at screening (D-2).
  • Smoking >5 cigarettes/day or habitual use of nicotine-containing products within 3 months before screening, and unable to abstain during the study.
  • History of alcohol abuse within 1 year before screening (male: >14 standard units/week; 1 unit = 14 g alcohol, e.g., 360 mL beer, 45 mL 40% spirits, or 150 mL wine), or positive alcohol breath/blood test at screening.
  • Special dietary requirements and unable to accept the standardized diet.
  • Habitual intake of grapefruit juice or excessive tea, coffee, and/or caffeinated beverages (>8 cups, 1 cup = 250 mL) within 3 months before screening, and unable to abstain during the study.
  • Unable to avoid strenuous exercise or other behaviors that may affect PK parameters from 48 h before dosing through the entire study.
  • History of needle or blood phobia, difficult blood collection, or intolerance to venipuncture.
  • Use of any medication within 28 days or 5 elimination half-lives before first dose, whichever is longer, including prescription drugs, OTC drugs, herbal medicines, Chinese patent medicines, or nutritional supplements.
  • within 1 month before screening, or planned vaccination during the study.
  • Participation in any clinical trial within 3 months before screening (except ICF signing only without drug/device intervention), or last dose of drug \<5 half-lives before screening.
  • Occupational long-term radiation exposure; or significant radiation exposure within 1 year before the study (e.g., ≥2 chest/abdominal CT scans or ≥3 other types of X-ray examinations); or planned radiological diagnosis/treatment within 1 year after the study; or participation in a clinical trial involving radiolabeled drugs within 1 year.
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for the trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    [14C] DA-302168S

    A single dose of \[14C\] DA-302168S administered orally.

    Drug: [14C] DA-302168S

Interventions

06

What researchers measure

Primary outcomes

  1. Total recovery of DA-302168S radioactivity in urine and feces, following oral administration of [14C] DA-302168S

    Time frame: Predose up to Day 8 after administration of [14C]DA-302168S

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Dec 20, 2026
CompletionEst.
Dec 20, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedTotal recovery of HDM1002DA-302168S radioactivity in urine and feces, following oral administration of [14C] DA-302168STime frame: Predose up to Day 8 after administration of [14C]DA-302168S
  • RemovedIdentification of Major Metabolites in Human Plasma, Urine, and FecesTime frame: Predose up to Day 8 after administration of [14C]DA-302168S
Oct 15, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 15, 2026
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedTotal recovery of HDM1002DA-302168S radioactivity in urine and feces, following oral administration of [14C] DA-302168STime frame: Predose up to Day 8 after administration of [14C]DA-302168S
    • RemovedIdentification of Major Metabolites in Human Plasma, Urine, and FecesTime frame: Predose up to Day 8 after administration of [14C]DA-302168S
    + 3 other changes: verification date, arm descriptions and criteria formatting
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857265
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Oct 15, 2026

Study contacts

qin xiaolong
Contact
qinxiaolong.cn@outlook.com
18781997925

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DA-302168S

Start the discussion